Dolutegravir is an integrase strand transfer inhibitor (INSTI), the latest class of drugs to be added to antiretroviral therapy. Dolutegravir works by preventing the integrase enzyme from transferring the viral DNA strand into the T-cell DNA strand. Without integrating with the T-cell DNA, HIV-1 cannot replicate itself and gets degraded.

Dolutegravir (DTG), sold under the brand name Tivicay, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS. [6] . It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following potential exposure. [7] …

Dolutegravir/lamivudine/tenofovir (DTG/3TC/TDF) is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. [1] . It is a combination of dolutegravir, lamivudine, and tenofovir disoproxil. [1] .

2019年7月24日 · Two drugs under consideration for inclusion in new regimens are dolutegravir (DTG), to replace EFV, and tenofovir alafenamide fumarate (TAF), to replace TDF, both prodrugs of tenofovir. 7,8 DTG has...

The data on safety and efficacy of DTG-containing regimens were also reviewed, addressing key considerations associated with newer antiretroviral (ARV) drugs – including body weight gain and other cardiometabolic risks, tolerability of regimens, safety in pregnancy and HIV drug resistance.

Dolutegravir is used to treat HIV infection. Dolutegravir is available under the following different brand names: Tivicay. What Are Dosages of Dolutegravir? Tablet. Pediatric Dosage Forms …

2025年1月1日 · TLD is a generic HIV combination. It contains tenofovir disoproxil, lamivudine and dolutegravir. Sometime the tablet are marked LTD. TLD is a very good combination and is now the most widely used ART. It is recommended by the WHO. This combination is only available in either low or middle-income countries.

TLD is a fixed-dose combination of TDF 300 mg, 3TC 300 mg, and DTG 50 mg. TLD is also recommended for use as a second-line regimen for patients failing on efavirenz- or nevirapine-containing regimens or for those failing a non-DTG-containing first-line regimen. WHY TRANSITION FROM TLE TO TLD?

2024年4月27日 · Dolutegravir is used together with other medicines for the treatment of the infection caused by human immunodeficiency virus (HIV) in patients who have not received …

Dolutegravir/rilpivirine (DTG/RPV) was approved by the US Food and Drug Administration (FDA) as the first dual antiretroviral STR for the maintenance therapy of HIV-1 infection.